Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02949726 · ClinicalTrials.gov registry record · Phase 1
Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT02949726: Completed Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
NCT02949726 is a Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02949726, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The goal of this study is to find out which immune molecules, cells, and genes are involved in the development of lymphedema (LE), so that medicines that target them can be considered for treating lymphedema. The hypothesis is that LE is a systemic, autoimmune-like disease that is initiated by inflammatory cytokines induced by surgery, radiation, and possibly chemotherapy in genetically susceptible patients.
Interventions
- DRUG Indocyanine Green (ICG)
- DEVICE Near-infrared Fluorescence Lymphatic Imaging (NIRFLI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2022-10-01 |
| Phase | Phase 1 |
What the finished NCT02949726 record still lists
NCT02949726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 2 interventions - of which Indocyanine Green (ICG) is the first listed.
NCT02949726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02949726 about?
NCT02949726 is a clinical study titled "Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development". The goal of this study is to find out which immune molecules, cells, and genes are involved in the development of lymphedema (LE), so that medicines that target them can be considered for treating lymphedema. The hypothesis is that LE is a systemic, autoimmune-like disease that is initiated by infla...
What is the current status of trial NCT02949726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2017-04-24. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT02949726?
The interventions under investigation include: Indocyanine Green (ICG) (DRUG), Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) (DEVICE).
Who is sponsoring clinical trial NCT02949726?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02949726's enrollment target sits among peer trials
80 672nd of 2000 higher than 1,305 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI